Rimon Therapeutics Named One of
Nov 27, 2006 - 09:58
"We appreciate being recognized as one of
The award comes only a few months after Rimon was recognized at another high-profile Canadian biotechnology event: Rimon was named "Most Promising Early Stage Company" at CANMEDBIO 2006's National Presidents' Awards, on June 19, 2006.
As one of
About Rimon Therapeutics
Rimon Therapeutics Ltd. is the Theramer™ Company. Theramers™ (therapeutic polymers) are polymers that have drug-like activity, but can be marketed and regulated as devices. Rimon's Theramers™ induce the development of new blood vessels, prevent the destruction of tissue, and kill bacteria without harming human cells. The company is engaging some of the world's largest medical device companies about using these unique polymers to heal chronic wounds (e.g., bedsores and diabetic ulcers), treat heart disease, delay knee replacement, and prevent medical device-related infections. Preliminary results from the Company's first, human clinical trial of its MI-Sorb(TM) Dressing for chronic wounds are very promising and represent a key milestone in the validation of Rimon's unique, value proposition-drug-like margins and device timelines, together with the versatility of polymer chemistry.
FOR FURTHER INFORMATION PLEASE CONTACT:
Rimon Therapeutics Ltd.
Dr. Michael May, PhD
President
416-977-2003
may@rimontherapeutics.com
or
Media Contact:
What If What Next
Howard Oliver
416-638-8582